<DOC>
	<DOCNO>NCT00568893</DOCNO>
	<brief_summary>This trial obtain safety data adult patient severe sepsis two sepsis-induced organ infection receive infusion drotrecogin alfa ( activate ) .</brief_summary>
	<brief_title>An Open Label Study Severe Sepsis Adults</brief_title>
	<detailed_description>To collect safety data provide drotrecogin alfa ( activate ) treatment patient severe sepsis multiple organ dysfunction . Patient access drotrecogin alfa ( activate ) provide protocol prior review Authorities Belgium Luxemburg commercial release .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Drotrecogin alfa activate</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<criteria>Patients great equal 18 year age may include study meet follow criterion : 1 . Must 18 year . 2 . Suspected proven infection 3 . Have two sepsisinduced organ failure sepsis Patients exclude entry study follow reason : 1 . Documented first organ dysfunction great 48hours prior start study drug . 2 . Patients great 135 kg weight . 3 . Patients platelet count less 30,000/mm3 4 . Active internal bleeding increase risk bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>